Immunologic Research

, Volume 56, Issue 2–3, pp 299–303 | Cite as

Adverse events following immunization with vaccines containing adjuvants

  • S. Cerpa-CruzEmail author
  • P. Paredes-Casillas
  • E. Landeros Navarro
  • A. G. Bernard-Medina
  • G. Martínez-Bonilla
  • S. Gutiérrez-Ureña
Etio Pathogenesis of Autoimmunity


A traditional infectious disease vaccine is a preparation of live attenuated, inactivated or killed pathogen that stimulates immunity. Vaccine immunologic adjuvants are compounds incorporated into vaccines to enhance immunogenicity. Adjuvants have recently been implicated in the new syndrome named ASIA autoimmune/inflammatory syndrome induced by adjuvants. The objective describes the frequencies of post-vaccination clinical syndrome induced by adjuvants. We performed a cross-sectional study; adverse event following immunization was defined as any untoward medical occurrence that follows immunization 54 days prior to the event. Data on vaccinations and other risk factors were obtained from daily epidemiologic surveillance. Descriptive statistics were done using means and standard deviation, and odds ratio adjusted for potential confounding variables was calculated with SPSS 17 software. Forty-three out of 120 patients with moderate or severe manifestations following immunization were hospitalized from 2008 to 2011. All patients fulfilled at least 2 major and 1 minor criteria suggested by Shoenfeld and Agmon–Levin for ASIA diagnosis. The most frequent clinical findings were pyrexia 68 %, arthralgias 47 %, cutaneous disorders 33 %, muscle weakness 16 % and myalgias 14 %. Three patients had diagnosis of Guillain–Barre syndrome, one patient had Adult-Still’s disease 3 days after vaccination. A total of 76 % of the events occurred in the first 3 days post-vaccination. Two patients with previous autoimmune disease showed severe adverse reactions with the reactivation of their illness. Minor local reactions were present in 49 % of patients. Vaccines containing adjuvants may be associated with an increased risk of autoimmune/inflammatory adverse events following immunization.


Adjuvant Vaccines Autoimmunity Aluminum Thiomersal Syndrome 


  1. 1.
    Nakayama T. Influenza vaccine and adjuvant. Yakugaku Zasshi. 2011;131(12):1723–31.PubMedCrossRefGoogle Scholar
  2. 2.
    Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert Rev Vaccines. 2007;6(5):673–84.PubMedCrossRefGoogle Scholar
  3. 3.
    Cruz-Tapias P, et al. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr Opin Rheumatol. 2012;24(4):389–93.PubMedCrossRefGoogle Scholar
  4. 4.
    de Veer M, Meeusen E. New developments in vaccine research—unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195–204.PubMedGoogle Scholar
  5. 5.
    Leitner WW. Vaccine adjuvants: is the pipeline clogged? Immunotherapy. 2012;4(6):565–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Schijns VE, Lavelle EC. Trends in vaccine adjuvants. Expert Rev Vaccines. 2011;10(4):539–50.PubMedCrossRefGoogle Scholar
  7. 7.
    Shoenfeld Y, Agmon-Levin N. ‘ASIA’ - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun. 2011;36(1):4–8.PubMedCrossRefGoogle Scholar
  8. 8.
    WHO. Surveillance of adverse events following immunization. Field guide for managers of immunization programmes. Geneva. 1997.Google Scholar
  9. 9.
    WHO. Supplementary information on vaccine safety. Part 2. Background rates of adverse events following immunization. Geneva. 2000.Google Scholar
  10. 10.
    Vitoriano-Souza J, et al. Cell recruitment and cytokines in skin mice sensitized with the vaccine adjuvants: saponin, incomplete Freund’s adjuvant, and monophosphoryl lipid A. PLoS One. 2012;7(7):e40745.PubMedCrossRefGoogle Scholar
  11. 11.
    Levy O, Goriely S, Kollmann TR. Immune response to vaccine adjuvants during the first year of life. Vaccine. 2012.Google Scholar
  12. 12.
    Katzav A, Kivity S, Blank M, Shoenfeld Y, Chapman J. Adjuvant immunization induces high levels of pathogenic antiphospholipid antibodies in genetically prone mice: another facet of the ASIA syndrome. Lupus. 2012;21:210–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Lerner A. Aluminum as an adjuvant in Crohn’s disease induction. Lupus. 2012;21(2):231–8.PubMedCrossRefGoogle Scholar
  14. 14.
    Zafrir Y, et al. Autoimmunity following hepatitis B vaccine as part of the spectrum of ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’ (ASIA): analysis of 93 cases. Lupus. 2012;21(2):146–52.PubMedCrossRefGoogle Scholar
  15. 15.
    Perdan-Pirkmajer K, et al. Autoimmune response following influenza vaccination in patients with autoimmune inflammatory rheumatic disease. Lupus. 2012;21(2):175–83.PubMedCrossRefGoogle Scholar
  16. 16.
    Ray P, et al. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15–59 years of age. Vaccine. 2011;29(38):6592–7.PubMedCrossRefGoogle Scholar
  17. 17.
    Tomljenovic L, Shaw CA. Mechanisms of aluminum adjuvant toxicity and autoimmunity in pediatric populations. Lupus. 2012;21(2):223–30.PubMedCrossRefGoogle Scholar
  18. 18.
    Lukiw WJ, Percy ME, Kruck TP. Nanomolar aluminum induces pro-inflammatory and pro-apoptotic gene expression in human brain cells in primary culture. J Inorg Biochem. 2005;99(9):1895–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Eisenbarth SC, et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature. 2008;453(7198):1122–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Gherardi RK, Authier FJ. Macrophagic myofasciitis: characterization and pathophysiology. Lupus. 2012;21(2):184–9.PubMedCrossRefGoogle Scholar
  21. 21.
    Agmon-Levin N, Hughes GR, Shoenfeld Y. The spectrum of ASIA: ‘Autoimmune (Auto-inflammatory) Syndrome induced by Adjuvants’. Lupus. 2012;21(2):118–20.PubMedCrossRefGoogle Scholar
  22. 22.
    Exley C, Siesjo P, Eriksson H. The immunobiology of aluminium adjuvants: how do they really work? Trends Immunol. 2010;31(3):103–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Whitehouse M. Oily adjuvants and autoimmunity: now time for reconsideration? Lupus. 2012;21(2):217–22.PubMedCrossRefGoogle Scholar
  24. 24.
    Lerner A. Aluminum as an adjuvant in Crohn’s disease induction. Lupus. 2012;21(2):231–8.PubMedCrossRefGoogle Scholar
  25. 25.
    Barile JP, et al. Thimerosal exposure in early life and neuropsychological outcomes 7–10 years later. J Pediatr Psychol. 2012;37(1):106–18.PubMedCrossRefGoogle Scholar
  26. 26.
    Madi A. Being on the track of thimerosal. Review. Acta Microbiol Immunol Hung. 2005;52(1):95–103.PubMedCrossRefGoogle Scholar
  27. 27.
    Barregard L, et al. Toxicokinetics of mercury after long-term repeated exposure to thimerosal-containing vaccine. Toxicol Sci. 2011;120(2):499–506.PubMedCrossRefGoogle Scholar
  28. 28.
    Soriano A, et al. Giant cell arteritis and polymyalgia rheumatica after influenza vaccination: report of 10 cases and review of the literature. Lupus. 2012;21(2):153–7.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • S. Cerpa-Cruz
    • 1
    Email author
  • P. Paredes-Casillas
    • 2
  • E. Landeros Navarro
    • 2
  • A. G. Bernard-Medina
    • 1
  • G. Martínez-Bonilla
    • 1
  • S. Gutiérrez-Ureña
    • 1
  1. 1.Rheumatology and Immunology DepartmentHospital Civil de Guadalajara “Fray Antonio Alcalde”GuadalajaraMexico
  2. 2.Internal Medicine and Epidemiology DepartmentHospital Civil de Guadalajara “Fray Antonio Alcalde”GuadalajaraMexico

Personalised recommendations